Ganesh S. Palapattu
YOU?
Author Swipe
View article: Molecular Profiling of Primary versus Paired Asynchronous Metastatic Clear Cell Renal Cell Carcinoma Reveals Heterogeneity in Tumor Immune Microenvironment
Molecular Profiling of Primary versus Paired Asynchronous Metastatic Clear Cell Renal Cell Carcinoma Reveals Heterogeneity in Tumor Immune Microenvironment Open
Background and Objective: The tumor immune microenvironment (TIME) shows significant heterogeneity in primary clear cell renal cell carcinoma (ccRCC). As TIME heterogeneity between primary and paired metastatic tumors of ccRCC is less unde…
View article: Prostate Cancer Foundation White Paper on Combination Therapy for Metastatic Hormone-Sensitive Prostate Cancer
Prostate Cancer Foundation White Paper on Combination Therapy for Metastatic Hormone-Sensitive Prostate Cancer Open
Despite several randomized controlled trials demonstrating the benefits of combination therapies for metastatic hormone-sensitive prostate cancer (mHSPC), a significant treatment gap persists. This initiative by the Prostate Cancer Foundat…
View article: Clinical Validation of MyProstateScore 2.0 Testing Using First-Catch, Non–Digital Rectal Examination Urine
Clinical Validation of MyProstateScore 2.0 Testing Using First-Catch, Non–Digital Rectal Examination Urine Open
Using first-catch urine, MPS2 meaningfully improved the proportion of biopsies avoided relative to PCPTrc while maintaining highly sensitive detection of GG ≥ 2 cancer. Non-DRE testing provides a convenient, objective, and highly accurate …
View article: Differences in mutations across tumour sizes in clear‐cell renal cell carcinoma
Differences in mutations across tumour sizes in clear‐cell renal cell carcinoma Open
Objective To assess the distribution of key mutations across tumour sizes in clear‐cell renal cell carcinoma (ccRCC), and secondarily to examine the prognostic impact of aggressive mutations in smaller ccRCCs. Patient and Methods The distr…
View article: Serum Androgens as Predictive Biomarkers: Results From a Randomized Clinical Trial Comparing Enzalutamide and Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer
Serum Androgens as Predictive Biomarkers: Results From a Randomized Clinical Trial Comparing Enzalutamide and Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer Open
Pre-treatment serum testosterone levels may be a clinically useful biomarker for predicting mCRPC treatment responses and guiding treatment selection.
View article: Table of Contents
Table of Contents Open
View article: Integrative multi-region molecular profiling of primary prostate cancer in men with synchronous lymph node metastasis
Integrative multi-region molecular profiling of primary prostate cancer in men with synchronous lymph node metastasis Open
Localized prostate cancer is frequently composed of multiple spatially distinct tumors with significant inter- and intra-tumoral molecular heterogeneity. This genomic diversity gives rise to many competing clones that may drive the biologi…
View article: Development and Validation of an 18-Gene Urine Test for High-Grade Prostate Cancer
Development and Validation of an 18-Gene Urine Test for High-Grade Prostate Cancer Open
Importance Benefits of prostate cancer (PCa) screening with prostate-specific antigen (PSA) alone are largely offset by excess negative biopsies and overdetection of indolent cancers resulting from the poor specificity of PSA for high-grad…
View article: Analyzing the Current State and Visibility of Diversity, Equity, and Inclusion Initiatives at Urology Residency Programs
Analyzing the Current State and Visibility of Diversity, Equity, and Inclusion Initiatives at Urology Residency Programs Open
Less than half of academic urology programs' websites referenced DEI initiatives. Using a DEI score card, our study shows that investment in DEI varies widely by AUA section, and greater investment is positively correlated with program ran…
View article: Analysis of the Tumor Immune Microenvironment (TIME) in Clear Cell Renal Cell Carcinoma (ccRCC) Reveals an M0 Macrophage-Enriched Subtype: An Exploration of Prognostic and Biological Characteristics of This Immune Phenotype
Analysis of the Tumor Immune Microenvironment (TIME) in Clear Cell Renal Cell Carcinoma (ccRCC) Reveals an M0 Macrophage-Enriched Subtype: An Exploration of Prognostic and Biological Characteristics of This Immune Phenotype Open
There is a need to optimize the treatment of clear cell renal cell carcinoma (ccRCC) patients at high recurrence risk after nephrectomy. We sought to elucidate the tumor immune microenvironment (TIME) of localized ccRCC and understand the …
View article: Table of Contents
Table of Contents Open
View article: Spatial Heterogeneity of Glomerular Phenotypes Affects Kidney Biopsy Findings
Spatial Heterogeneity of Glomerular Phenotypes Affects Kidney Biopsy Findings Open
Key Points Glomeruli with pathologic changes are not homogeneously distributed throughout the kidney cortex. Biopsies that do not include the kidney capsule may underdetect glomeruli with pathologic changes. Location of glomeruli with path…
View article: Role of Adenosine Deaminase in Prostate Cancer Progression
Role of Adenosine Deaminase in Prostate Cancer Progression Open
Prostate cancer (PCa) is the second most common cancer and constitutes about 14.7% of total cancer cases. PCa is highly prevalent and more aggressive in African American (AA) men when compared to European-American (EA) men. PCa tends to be…
View article: Comparing Patient-reported Functional Outcomes After Radical Prostatectomy in Historical and Contemporary Practice
Comparing Patient-reported Functional Outcomes After Radical Prostatectomy in Historical and Contemporary Practice Open
Our results demonstrate that the widespread alterations in prostate cancer surgery over the past 2 decades have yielded improvements in sexual, but not urinary, function recovery.
View article: Integrative multi-region molecular profiling of primary prostate cancer with synchronous lymph node metastasis to characterize the biologically dominant clone
Integrative multi-region molecular profiling of primary prostate cancer with synchronous lymph node metastasis to characterize the biologically dominant clone Open
Localized prostate cancer is composed of multiple spatially distinct tumors with significant inter- and intra-tumoral molecular heterogeneity. This genomic diversity gives rise to many competing subclones that may drive the biological traj…
View article: Current Landscape of Genomic Biomarkers in Clear Cell Renal Cell Carcinoma
Current Landscape of Genomic Biomarkers in Clear Cell Renal Cell Carcinoma Open
View article: Development and Validation of MyProstateScore 2.0 to Detect Clinically Significant Prostate Cancer
Development and Validation of MyProstateScore 2.0 to Detect Clinically Significant Prostate Cancer Open
Background The benefits of prostate cancer screening with serum prostate-specific antigen (PSA) have been largely offset by the high rate of negative prostate biopsies and overdiagnosis of indolent cancers. These outcomes result from the l…
View article: Supplementary Tables S1 - S6 from Biallelic Alteration and Dysregulation of the Hippo Pathway in Mucinous Tubular and Spindle Cell Carcinoma of the Kidney
Supplementary Tables S1 - S6 from Biallelic Alteration and Dysregulation of the Hippo Pathway in Mucinous Tubular and Spindle Cell Carcinoma of the Kidney Open
Supplementary Tables S1 - S6. Supplementary Table S1. Patient clinical characteristics and summary of the observed molecular aberrations in the MTSCC cases studied. Supplementary Table S2. Sequencing quality metrics. Supplementary Table S3…
View article: Data from Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature
Data from Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature Open
The trend toward precision-based therapeutic approaches dictated by molecular alterations offers substantial promise for men with metastatic castration-resistant prostate cancer (mCRPC). However, current approaches for molecular characteri…
View article: Supplementary Figure Legends, Table Legends from Biallelic Alteration and Dysregulation of the Hippo Pathway in Mucinous Tubular and Spindle Cell Carcinoma of the Kidney
Supplementary Figure Legends, Table Legends from Biallelic Alteration and Dysregulation of the Hippo Pathway in Mucinous Tubular and Spindle Cell Carcinoma of the Kidney Open
Supplementary Figure Legends, Table Legends
View article: Supplementary Tables S1 - S6 from Biallelic Alteration and Dysregulation of the Hippo Pathway in Mucinous Tubular and Spindle Cell Carcinoma of the Kidney
Supplementary Tables S1 - S6 from Biallelic Alteration and Dysregulation of the Hippo Pathway in Mucinous Tubular and Spindle Cell Carcinoma of the Kidney Open
Supplementary Tables S1 - S6. Supplementary Table S1. Patient clinical characteristics and summary of the observed molecular aberrations in the MTSCC cases studied. Supplementary Table S2. Sequencing quality metrics. Supplementary Table S3…
View article: Data from Biallelic Alteration and Dysregulation of the Hippo Pathway in Mucinous Tubular and Spindle Cell Carcinoma of the Kidney
Data from Biallelic Alteration and Dysregulation of the Hippo Pathway in Mucinous Tubular and Spindle Cell Carcinoma of the Kidney Open
Mucinous tubular and spindle cell carcinoma (MTSCC) is a relatively rare subtype of renal cell carcinoma (RCC) with distinctive morphologic and cytogenetic features. Here, we carry out whole-exome and transcriptome sequencing of a multi-in…
View article: Supplementary Figures S1 - S8 from Biallelic Alteration and Dysregulation of the Hippo Pathway in Mucinous Tubular and Spindle Cell Carcinoma of the Kidney
Supplementary Figures S1 - S8 from Biallelic Alteration and Dysregulation of the Hippo Pathway in Mucinous Tubular and Spindle Cell Carcinoma of the Kidney Open
Supplementary Figures S1 - S8. Supplementary Figure S1. Intra-tumor mutational heterogeneity in MTSCC. Supplementary Figure S2. Copy number variation and Hippo pathway mutation in the MTSCC validation cohort and the TCGA KIRP outlier sampl…
View article: Supplementary Figures S1 - S6, Tables S1 - S2 from Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature
Supplementary Figures S1 - S6, Tables S1 - S2 from Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature Open
Supplementary Figure S1: Evaluation of pre-amplication. Supplementary Figure S2: Algorithm for CTC positivity. Supplementary Figure S3: CTC isolation and gene analysis methodology. Supplementary Figure S4: Validation of gene expression. Su…
View article: Supplementary Figures S1 - S6, Tables S1 - S2 from Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature
Supplementary Figures S1 - S6, Tables S1 - S2 from Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature Open
Supplementary Figure S1: Evaluation of pre-amplication. Supplementary Figure S2: Algorithm for CTC positivity. Supplementary Figure S3: CTC isolation and gene analysis methodology. Supplementary Figure S4: Validation of gene expression. Su…
View article: Data from Biallelic Alteration and Dysregulation of the Hippo Pathway in Mucinous Tubular and Spindle Cell Carcinoma of the Kidney
Data from Biallelic Alteration and Dysregulation of the Hippo Pathway in Mucinous Tubular and Spindle Cell Carcinoma of the Kidney Open
Mucinous tubular and spindle cell carcinoma (MTSCC) is a relatively rare subtype of renal cell carcinoma (RCC) with distinctive morphologic and cytogenetic features. Here, we carry out whole-exome and transcriptome sequencing of a multi-in…
View article: Supplementary Figures S1 - S8 from Biallelic Alteration and Dysregulation of the Hippo Pathway in Mucinous Tubular and Spindle Cell Carcinoma of the Kidney
Supplementary Figures S1 - S8 from Biallelic Alteration and Dysregulation of the Hippo Pathway in Mucinous Tubular and Spindle Cell Carcinoma of the Kidney Open
Supplementary Figures S1 - S8. Supplementary Figure S1. Intra-tumor mutational heterogeneity in MTSCC. Supplementary Figure S2. Copy number variation and Hippo pathway mutation in the MTSCC validation cohort and the TCGA KIRP outlier sampl…
View article: Supplementary Figure Legends, Table Legends from Biallelic Alteration and Dysregulation of the Hippo Pathway in Mucinous Tubular and Spindle Cell Carcinoma of the Kidney
Supplementary Figure Legends, Table Legends from Biallelic Alteration and Dysregulation of the Hippo Pathway in Mucinous Tubular and Spindle Cell Carcinoma of the Kidney Open
Supplementary Figure Legends, Table Legends
View article: Data from Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature
Data from Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature Open
The trend toward precision-based therapeutic approaches dictated by molecular alterations offers substantial promise for men with metastatic castration-resistant prostate cancer (mCRPC). However, current approaches for molecular characteri…
View article: Data from Molecular Profiling to Determine Clonality of Serial Magnetic Resonance Imaging/Ultrasound Fusion Biopsies from Men on Active Surveillance for Low-Risk Prostate Cancer
Data from Molecular Profiling to Determine Clonality of Serial Magnetic Resonance Imaging/Ultrasound Fusion Biopsies from Men on Active Surveillance for Low-Risk Prostate Cancer Open
Purpose: To determine whether MRI/ultrasound (MRI/US) fusion biopsy facilitates longitudinal resampling of the same clonal focus of prostate cancer and to determine whether high-grade cancers can evolve from low-grade clones.Expe…